1. Introduction
===============

Tuberculosis (TB) is one of the most serious infectious diseases worldwide and a leading cause of death for nearly 3 million deaths annually. In 2013, an estimated 9.0 million people were infected with tuberculosis, and 1.5 million died from this disease. In Iran, TB incidence was considerably lower than in neighboring countries over the last decade ([@b1-epj-08-3005]). TB is a highly prevalent chronic devastating disease caused by Mycobacterium tuberculosis. This bacteria is a sedentary, obligate aerobic, acid fast facultative intracellular rod-shaped bacterium, with long generation time and preference to localize in macrophage and typically affects the lungs (pulmonary TB) but can affect other sites as well as extra pulmonary TB ([@b2-epj-08-3005], [@b3-epj-08-3005]). The most common method to detect TB is sputum smear microscopy. In this method, bacteria are observed in sputum samples examined under a microscope. In areas with more equipped laboratories, cases of TB also are diagnosed via culture methods (the reference standard method). Following recent development in TB diagnostics, rapid molecular tests have been used for diagnosis of TB and drug-resistant TB ([@b4-epj-08-3005]). Treatments of tuberculosis involve the use of a mixture of drugs to hinder drug resistance. A composition of drugs is highly effective in treating tuberculosis, but it may also lead to enhanced toxicity and side effects. TB is treated with an initial intensive 2-month regimen consisting of multiple antibiotics, including rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB) or streptomycin (SM) to guarantee that mutants resistant to a single drug will not occur ([@b5-epj-08-3005], [@b6-epj-08-3005]). The four-drug combination therapy (isoniazid \[INH\], rifampin \[RIF\], pyrazinamide \[PZA\], and ethambutol \[EMB\]) is the main treatment of active tuberculosis, of which the first three are hepatotoxic. Multidrug-resistant strains, resistant to at least isoniazid and rifampicin, requires our attention because they requires the use of second-line drugs that are difficult to procure and are much more toxic and expensive than the first-line regimen ([@b7-epj-08-3005], [@b8-epj-08-3005]). Indicators of hepatocellular functions that usually are assayed in clinical toxicology studies are the enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Changes in concentrations of the exudation enzymes ALT and AST show changes in cell membrane function, such as changes in permeability or the more obvious cell membrane disconnection ([@b5-epj-08-3005], [@b9-epj-08-3005]). In tuberculosis, many hematological and biochemical abnormalities are common, and they are valuably aiding to patients' management and diagnosis. Tuberculosis patients may have a rise in hemoglobin and hematocrit levels due to the response to treatment. Hematological abnormalities associated with TB infection have, to the best of our knowledge, been incompletely investigated ([@b4-epj-08-3005], [@b5-epj-08-3005]). As a nonspecific test for inflammatory and infectious processes, erythrocyte sedimentation rate (ESR) is used to evaluate activity level and disease extent, response to treatment, and the prognosis of subacute and chronic diseases such as tuberculosis. The reduction in this test was regarded as a good index to observe the drug response and disease progress or regress ([@b10-epj-08-3005], [@b11-epj-08-3005]). In line with our recent studies on the effect of different compounds on liver function and blood factors ([@b12-epj-08-3005]--[@b16-epj-08-3005]), this study was designed to observe the hematological and biochemical changes and associated risk factors in smear positive pulmonary tuberculosis patients undergoing treatment with standard protocol.

2. Material and Methods
=======================

2.1. Study design and setting
-----------------------------

This descriptive study was conducted on patients with pulmonary tuberculosis who were treated with standard protocol in the hospitals of Khuzestan Province (Iran) from March 2013 to March 2014. A total of 40 male and female tuberculosis patients aged 15--60 years were included in this study. Subjects were selected from among smear positive pulmonary tuberculosis patients who were referred to TB reference of Khuzestan province. Exclusion criteria were HIV positive, pregnancy, chronic and acute liver disease, and multidrug-resistant tuberculosis patients. The drug regimens were isoniazid, rifampicin, ethambutol and pyrazinamide during the initial two months, followed by isoniazid and rifampicin for the next four to six months ([@b5-epj-08-3005], [@b12-epj-08-3005]). Patients with pulmonary tuberculosis were selected among patients with tuberculosis reference laboratory province. Exclusion criteria were the presence of diseases other than tuberculosis (like HIV). Also patients with drug-resistant tuberculosis were excluded from the study.

2.2. Blood collection and processing
------------------------------------

After identification, about 3--4 ml peripheral venous blood was drawn aseptically by sterile syringe: 2 ml was transferred into a tube containing 0.2 ml of 4% ethylene diamine tetra acetic acid (EDTA) solution, and then it was analyzed in the hematology analyzer (Sysmex, KX-21) for evaluation of different blood parameters including hemoglobin (Hb); total leukocyte count (TLC); and differentiation neutrophils; monocytes and lymphocytes; red blood cell(RBC); platelet count; hematocrit (HCT); mean corpuscular volume (MCV); mean corpuscular hemoglobin (MCH); mean corpuscular hemoglobin concentration (MCHC); in addition, 2 ml of the blood were used for erythrocytic sedimentation rate (ESR) determination.

2.3. Liver function test
------------------------

The routine laboratory testing was performed at the Central Pathology Laboratory, including AST, ALT, and alkaline phosphatase (ALP) as a liver function test.

2.4. Statistical analysis
-------------------------

Data is presented as mean ± Standard Deviation (S.D.) and were compared using the paired samples t-test for continuous variables and Wilcoxon test. SPSS version 16.0 was used for analyzing the data, and p-values ≤ 0.05 were considered significant.

3. Results
==========

A total of 40 male and female smear positive pulmonary tuberculosis patients from the TB reference laboratory were selected to evaluate different hematological parameters and some liver function enzymes. About 70% of patients over 50 years old, 30% were children, and about 80% were men. As shown in [Table 1](#t1-epj-08-3005){ref-type="table"}, there are significant changes in enzymatic and hematological parameters of tuberculosis patients before and after the treatment course. The mean of hematological parameter (RBC, Hb, HCT, MCV, MCH, and MCHC) in the study groups was significantly increased in patients after using the drugs, in comparison to before using the drugs (p\<0.001) ([Table 1](#t1-epj-08-3005){ref-type="table"}).

The mean of the Hb was significantly increased in patients after using drugs (13.45 ± 1.31) compared with before using drugs (12.92 ± 1.44). Also the hematocrit percentage was increased in the patient to after using drugs (40.35 ± 3.77) compared with before using the drugs (39.00 ± 3.66). The WBC and platelet counts, leukocyte count, and neutrophil count of tuberculosis patients were investigated before and after using drug. The mean of WBC before using drugs was 9.85 ± 2.41 and after drugs was 8.05 ± 1.56. Before using the drugs, neutrophil was 65.97 ± 9.77; after using drugs, it was 60.05 ± 6.59, which shows a significant decrease (p\<0.001). Before using the drugs, Lym was 33.92 ± 9.68; after using drugs, it was 37.80 ± 8.45, which shows a significantly increase (p\<0.01) ([Table 1](#t1-epj-08-3005){ref-type="table"}). According to [Table 1](#t1-epj-08-3005){ref-type="table"}, in this study, platelet count before using drugs was 294.17 ± 91.97; after using drugs, it was 303.42 ± 98.42; thus, difference was not significant. In this work, it has been found that the values of ESR for tuberculosis patients before using drugs (35.72 ± 10.83) are highly significantly increased (p\<0.001) compared with after using drugs (21.05 ± 6.04) ([Table 1](#t1-epj-08-3005){ref-type="table"}). The present study showed that there was a significant decrease (p\<0.001) in liver enzymes. ALP before using the drug was 208.82 ± 34.01; after using the drug, it was 160.15 ± 21.20. AST before using the drug was 44.47 ± 13.37; after using the drug, it was 28.22 ± 8.14. ALT before the drug was 40.22 ± 13.40; after using the drug, it was 27.05 ± 7.26.

4. Discussion
=============

Tuberculosis remains a main public health problem in developing countries, as it is the largest cause of death in the world as an individual infectious disease. There is not much literature about the hematological parameters in pulmonary TB patients in Iran's population ([@b17-epj-08-3005], [@b18-epj-08-3005]). This study reveals the hematological profile and some biochemical parameters in pulmonary tuberculosis patients. As shown in the results section, the values of red cell parameters---including RBC, Hb, HCT MCV, MCH, and MCHC---were significantly increased in patients after treatment. This finding is similar to studies by Araujo et al., Subodh kumar et al., and Shafee et al., which showed decreased levels of hemoglobin in patients ([@b19-epj-08-3005], [@b20-epj-08-3005]). Some previous studies conducted by Lombard and Mansvelt and Charles et al., also reported anemia in most tuberculosis patients ([@b16-epj-08-3005], [@b19-epj-08-3005]). It has been reported that lower MCHC values may be associated with deficiency of iron, which may be acquired through extrinsic factors ([@b4-epj-08-3005], [@b20-epj-08-3005]). Kumar Thatoi et al. have reported the tumor necrosis factor--α (TNF-α), and other cytokines released by activated monocytes suppress the erythropoietin production leading to anemia ([@b20-epj-08-3005]--[@b22-epj-08-3005]). This decrease in hemoglobin also might be due to the effects of anti-tuberculosis drugs during the period of treatment ([@b2-epj-08-3005]). Tengku et al. found that the majority of patients had normocytic normochromic anemia with thrombocytosis. These findings are similar to a study by Morris et al. who found hematological abnormalities among their patients with pulmonary TB included normochromic normocytic anemia, thrombocytosis ([@b23-epj-08-3005]). In our study, the total white blood cells (WBC) count was higher (p\<0.01) before treatment, which is in agreement with many previous studies. Neutrophil composition was higher when compared after treatment, and it could be concluded that leukocytosis due to neutrophils is associated with TB ([@b24-epj-08-3005]). No significant increase was in the lymphocyte count in TB patients before treatment (p\<0.0001). However, there were some reports of lymphocytosis and lymphopenia. Lymphocytic reaction reported in pulmonary tissue decays nonspecific inflammation. Many authors reported lymphocytopenia, leucopenia, neutropenia in tuberculosis ([@b21-epj-08-3005]). Data resulting from this study showed that the mean platelet count did not show a significant increase, which is in contrast with other studies by Kartaloglu et al., Venom, AL-Omar et al., and Awodu et al., who found that there was a significantly lower platelet count in African pulmonary tuberculosis patients ([@b4-epj-08-3005], [@b19-epj-08-3005]). Erythrocyte sedimentation rate at 30 and 60 minutes of pretreatment patients' mean value showed a highly significant increase with normal values (p\<0.01). In relation to ESR, some studies have shown that values were higher at pretreatment; as the beginning of the tuberculosis process, there is strong pro-inflammatory cytokine activity (IFN-γ and TNF-α), which stimulates the expression of acute-phase proteins and thrombocytosis. With disease evolution, which promotes cooling down of inflammatory activity ([@b4-epj-08-3005], [@b25-epj-08-3005]). Also Ukpe et al. found that active TB is associated mostly with very high ESR values (≥ 100mm/h) regardless of HIV condition, and that concomitant HIV infection tends to increase the proportion of TB cases with these very high values ([@b26-epj-08-3005]). In this study, after infection with M. tuberculosis, the aminotransferases (ALT, AST) levels significantly increased. The increment of liver enzyme levels did not reflect the bacterial load present. Drug treatment lead to a significant decrease of bacterial numbers, especially in combined drug treatment groups ([@b9-epj-08-3005], [@b27-epj-08-3005]). This finding was similar to that of Preeti Dharmik et al., who reported that, during anti-tuberculosis therapy, the level of the liver is elevated from its normal range, hence causing toxicity or malfunction of the human liver ([@b28-epj-08-3005]). Ashish Anantrao et al. showed that the ALP was used for distinguishing between tuberculosis and other types of pleural effusion ([@b29-epj-08-3005]). Hematological and biochemical indices in pulmonary tuberculosis are common and may be valuables to detect disease. Changes in some hematological parameters may reflect response to treatments ([@b23-epj-08-3005]). There are useful indices of severity in tuberculosis, and the return of these indicators to a normal level is a good symptom of disease control in that they are correlated with sputum exchange to negative acid-fast bacilli ([@b19-epj-08-3005]). There are some parts that may be improved in our retrospective study. The results obtained are clearly not representative of all tuberculosis patients, and the outcomes of all patients are not included because of deficient patient records. Another limitation is interactions between anti-TB drugs and other drugs in patients with comorbidity.

5. Conclusions
==============

In summary, this study shows that hematologic parameters and liver enzyme changes in pulmonary TB patients, which is associated with anti-TB drugs. After using drug treatments, hematological parameters (RBC, Hb, HCT, MCV, MCH, and MCHC), except platelet count were changed significantly. Liver enzyme activities (ALT, AST, and ALP) were decreased significantly (p ≤ 0.001) after treatment. The anti-tuberculosis drugs impose a hazardous effect on the patient's liver, leading to hepatotoxicity, and are a major problem in tuberculosis patients. This can be useful in determining response to treatment progress. Prospective studies are necessary to confirm this relationship.
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Changes in serum parameters in TB patients before and after treatments.

  Parameters        Pre (Mean ± SD)   Post (Mean ± SD)   Pre--Post (Mean ± SD)   *p*-value
  ----------------- ----------------- ------------------ ----------------------- -----------
  WBC (×10^9^ L)    9.85 ± 2.41       8.05 ± 1.56        1.79 ± 1.42             0.000
  RBC (×10 ^12^L)   4.87 ± 0.46       4.92 ± 0.48        0.49 ± 0.72             0.000
  Hb (g/dl)         12.92 ± 1.44      13.45 ± 1.31       0.53 ± 0.49             0.000
  Hct (%)           39.00 ± 3.66      40.35 ± 3.77       1.35 ± 0.88             0.000
  MCV (fl)          80.71 ± 9.26      81.87 ± 8.95       1.16 ± 1.11             0.000
  MCH (pg)          26.75 ± 3.40      27.62 ± 3.22       0.87 ± 0.70             0.000
  MCHC (g/dl)       33.12 ± 1.29      33.84 ± 1.34       0.72 ± 0.55             0.000
  Plt (×10 ^9^L)    294.17 ± 91.97    303.42 ± 98.42     9.25 ± 34.10            0.094
  Neu (%)           65.97 ± 9.77      60.05 ± 6.59       5.92 ± 6.99             0.000
  Lym (%)           33.92 ± 9.68      21.05 ± 6.04       14.67 ± 8.23            0.002
  ESR (mm/hr)       35.72 ± 10.83     37.80 ± 8.45       3.87 ± 7.51             0.000
  AST (IU/L)        44.47 ± 13.37     28.22 ± 8.14       16.25 ± 9.64            0.000
  ALT (IU/L)        40.22 ± 13.40     27.05 ± 7.26       13.17 ± 10.59           0.000
  ALP (IU/L)        208.82 ± 34.01    160.15 ± 21.20     48.67 ± 23.90           0.000

WBC: white blood cell; RBC: red blood cell; Hb: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; Plt: platelet count; Neu: neutrophils; Lym: lymphocytes; ESR: erythrocytic sedimentation rate; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase
